Literature DB >> 1707726

Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease.

G M Murphy1, L F Eng, W G Ellis, G Perry, L C Meissner, J R Tinklenberg.   

Abstract

Most patients with Down's syndrome (DS) undergo a premature cognitive decline with aging, and eventually develop the neuropathologic changes of Alzheimer's disease (AD), including amyloid-containing neuritic plaques, and the formation of neurofibrillary tangles. The amygdala is a focus of marked neuropathologic change in older patients with DS and in AD. We examined the amygdala with immunocytochemical and histochemical methods in 6 cases with DS, ages 19, 20, 27, 29, 56 and 64 years and compared them to 4 cases with AD, ages 54, 76, 77 and 80 years. An antiserum to the A4 amyloid peptide demonstrated amyloid deposition in plaques in all 10 cases. Plaques were also revealed in all cases by the Alcian blue stain for glycosaminoglycans and by the Bielschowsky and Bodian silver stains. An antiserum to alpha-1-antichymotrypsin (ACT) showed plaques in the AD cases and in the 19, 56 and 64 year old DS cases. Neurofibrillary tangles were observed with silver stains only in the older DS and in the AD cases, and not in the 19, 20, 27 and 29 year old DS cases. Likewise, antisera to paired helical filament, to microtubule associated proteins tau and microtubule associated protein-2 (MAP-2), and to ubiquitin, all of which are components of neurofibrillary tangles, reacted with tangles and abnormal neurites only in the older DS and the AD cases. An antiserum to neurofilament epitopes labeled NFTs in the older DS cases and the AD cases, but not in the younger DS cases, except for two intraneuronal NFTs in the 27 year old case.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1707726     DOI: 10.1016/0006-8993(90)90345-c

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 2.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

3.  Myelin basic protein associates with AβPP, Aβ1-42, and amyloid plaques in cortex of Alzheimer's disease brain.

Authors:  Xinhua Zhan; Glen C Jickling; Bradley P Ander; Boryana Stamova; DaZhi Liu; Patricia F Kao; Mariko A Zelin; Lee-Way Jin; Charles DeCarli; Frank R Sharp
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain.

Authors:  L S Higgins; G M Murphy; L S Forno; R Catalano; B Cordell
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

5.  Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease.

Authors:  G M Murphy; L S Forno; W G Ellis; D Nochlin; E Levy-Lahad; P Poorkaj; T D Bird; Z Jiang; B Cordell
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

6.  Identification of the Potential Key Circular RNAs in Elderly Patients With Postoperative Cognitive Dysfunction.

Authors:  Rui Gao; Chan Chen; Qi Zhao; Ming Li; Qiao Wang; Lu Zhou; Erya Chen; Hai Chen; Yue Zhang; Xingwei Cai; Changliang Liu; Xu Cheng; Shu Zhang; Xiaobo Mao; Yanhua Qiu; Lu Gan; Hai Yu; Jin Liu; Tao Zhu
Journal:  Front Aging Neurosci       Date:  2020-06-23       Impact factor: 5.750

Review 7.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Authors:  G M Murphy; L S Forno; L Higgins; J M Scardina; L F Eng; B Cordell
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

Review 9.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.

Authors:  Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom
Journal:  Nat Rev Neurosci       Date:  2015-08-05       Impact factor: 34.870

Review 10.  Nanomedicine-based immunotherapy for central nervous system disorders.

Authors:  Sumaira Hanif; Pir Muhammad; Rose Chesworth; Fawad Ur Rehman; Rong-Jun Qian; Meng Zheng; Bing-Yang Shi
Journal:  Acta Pharmacol Sin       Date:  2020-05-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.